Vo Van Cuong1, Bui Dang Minh Tri2, Bui Khanh Toan3
1 Health Department of Phu Tan District
2 Pham Ngoc Thach University of Medicine
3 Tay Nguyen Institute of Hygiene and Epidemiology

Nội dung chính của bài viết

Tóm tắt

Objective: To investigate the effect of Anthracyclines on left ventricular function on
breast cancer patients at Thong Nhat Hospital. Objects and methods: A prospective
descriptive study on 43 patients with breast cancer treated with Anthracyclines with
4 to 6 cycles as determined by the clinical doctor at Thong Nhat Hospital. Results:
Percentage of left ventricular ejection, total deformation of the vertical systolic stage
decreased significantly after treatment: EF before and after treatment were 60.23
± 3.46 and 59.44 ± 3,67 (%), respectively; GLS before and after treatment were
-20.01 ± 1.62 and -19.14 ± 1.82 (%), respectively. The incidence of cardiotoxicity
was 6.98%. The proportion of patients with subclinical left ventricular dysfunction
was 23.26%. After treatment, the proportion of respectively. The proportion of
patients with subclinical systolic dysfunction was higher in the decreased diastolic
function group compared to the group with normal diastolic function. Patients with
normal diastolic function after treatment decreased, the proportion of patients with
diastolic dysfunction increased significantly, accounting for 41.86% and 58.14%
No association was found between the type of anthracycline used, also disease
stage and the effect of anthracycline on left ventricular function. Conclusion: Left
ventricular ejection fraction, total deformation of the vertical systolic stage reduced.
The prevalence of cardiac toxicity and subclinical left ventricular dysfunction were
moderate. After treatment, the proportion of patients with normal diastolic function
decreased, the diastolic dysfunction increased. There was no relationship between the
type of Anthracycline used, also the disease stage and the effect of Anthracycline on
left ventricular function.

Chi tiết bài viết

Tài liệu tham khảo

[1] Peto R, Davies C et al., Comparisons
between different polychemotherapy
regimens for early breast cancer: Metaanalyses of long-term outcome among
100,000 women in 123 randomised trials.
Lancet, 379: 432–444, 2012.
[2] Qin A, Thompson CL, Silverman P,
Predictors of late-onset heart failure
in breast cancer patients treated with
doxorubicin. J Cancer Surviv, 9: 252–
259, 2015.
[3] Anita Boyd, Paul Stoodley, David
Richards et al., Anthracyclines induce
early changes in left ventricular systolic
and diastolic function: A single centre
study. PLoS ONE, 12(4): e0175544,
[4] Paul W. Stoodley, Left ventricular systolic
function in HER2/neu negative breast
cancer patients treated with anthracycline
chemotherapy: A comparative analysis
of left ventricular ejection fraction and
myocardial strain imaging over 12
months, 2013.
[5] Serrano JM, González I, Del Castillo S
et al., Diastolic Dysfunction Following
Anthracycline-Based Chemotherapy in
Breast Cancer Patients: Incidence and
Predictors. Oncologist, 20(8): 864-72,
[6] Negishi K, Negishi T, Hare JL,
Independent and incremental value of
deformation indices for prediction of
trastuzumab-induced cardiotoxicity. J
Am Soc Echocardiography, 26: 493–498,
[7] Mele D, Nardozza M, Spallarossa P
et al., Current views on anthracycline
cardiotoxicity. Heart Fail Rev, 21: 621–
634, 2016.
[8] Seicean S SA, Alan N, Plana JC et al.,
Cardioprotective effect of β-adrenoceptor
blockade in patients with breast cancer
undergoing chemotherapy: Follow-up
study of heart failure. Circ Heart Fail,
2013(6): 420–460, 2013.